Curated News
By: NewsRamp Editorial Staff
October 28, 2025
Cybin Raises $175M in Direct Offering for Mental Health Breakthroughs
TLDR
- Cybin's $175M funding round provides capital advantage to accelerate development of breakthrough mental health treatments ahead of competitors.
- Cybin issued 22.3M shares at $6.51 each with attached warrants exercisable at $8.14 under specific conditions to raise $175M for clinical trials.
- This funding advances Cybin's mission to revolutionize mental healthcare by developing effective treatments for major depressive disorder and anxiety disorders.
- Cybin's novel deuterated psilocin analog received FDA Breakthrough Therapy Designation and is now in Phase 3 trials for depression treatment.
Impact - Why it Matters
This funding represents a significant milestone in the development of novel mental health treatments at a time when depression and anxiety disorders affect hundreds of millions globally. Cybin's approach using psychedelic-inspired compounds could potentially revolutionize mental healthcare by providing more effective and durable treatments than current options. With traditional antidepressants often showing limited efficacy and significant side effects, breakthrough therapies like CYB003 and CYB004 could address critical gaps in mental health treatment, potentially offering faster-acting and more sustainable relief for patients who have found little success with existing medications. The substantial investment from major healthcare and biotech investors validates the scientific approach and suggests confidence in the potential regulatory and commercial success of these innovative treatments.
Summary
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a late-stage breakthrough neuropsychiatry company, has announced a significant registered direct offering of 22,277,750 common shares and pre-funded common share purchase warrants at US$6.51 per share, generating aggregate gross proceeds of US$175,009,911.45. This substantial capital raise demonstrates strong investor confidence in Cybin's innovative approach to mental healthcare, with participation from both new and existing institutional investors including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners and Ally Bridge Group. Each share or pre-funded warrant includes 0.35 of one common share purchase warrant exercisable at US$8.14 per share, with specific conditions tied to the company's clinical trial progress and stock performance.
The timing of this offering coincides with Cybin's advanced clinical development programs, particularly the APPROACH trial for CYB003 in major depressive disorder. The company's proprietary deuterated psilocin analog has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, positioning it as a potential game-changer in mental health treatment. Cybin is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in Phase 2 studies for generalized anxiety disorder, along with a broader research pipeline of investigational compounds focused on 5-HT receptors. The company's operational presence spans Canada, the United States, the United Kingdom, and Ireland, reflecting its global approach to addressing the substantial unmet needs in mental healthcare through novel therapeutic solutions.
This funding announcement was distributed through the InvestorBrandNetwork's Dynamic Brand Portfolio, which includes specialized communications platforms like InvestorWire that provide advanced wire-grade press release syndication services. The network offers comprehensive distribution capabilities including article and editorial syndication to over 5,000 outlets, enhanced press release optimization, social media distribution to millions of followers, and tailored corporate communications solutions. For investors seeking additional information about Cybin's developments, the company maintains an active newsroom accessible through the InvestorBrandNetwork platform, providing ongoing updates about their progress in revolutionizing mental healthcare treatment options.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cybin Raises $175M in Direct Offering for Mental Health Breakthroughs
